[1] |
SIEGEL R, MA J M, ZOU Z H, et al. Cancer statistics, 2023[J]. CA A Cancer J Clin, 2023, 73(1): 17-48.
doi: 10.3322/caac.v73.1
|
[2] |
CHEN P X, LIU Y H, WEN Y K, et al. Non-small cell lung cancer in China[J]. Cancer Commun (Lond), 2022, 42(10): 937-970.
|
[3] |
CHI Y J, WANG D, WANG J P, et al. Long non-coding RNA in the pathogenesis of cancers[J]. Cells, 2019, 8(9): 1015.
doi: 10.3390/cells8091015
|
[4] |
GE X L, LI G Y, JIANG L, et al. Long non-coding RNA CAR10 promotes lung adenocarcinoma metastasis via miR-203/30/SNAI axis[J]. Oncogene, 2019, 38(16): 3061-3076.
doi: 10.1038/s41388-018-0645-x
|
[5] |
JIANG M, QI F, ZHANG K, et al. MARCKSL1-2 reverses docetaxel-resistance of lung adenocarcinoma cells by recruiting SUZ12 to suppress HDAC1 and elevate miR-200b[J]. Mol Cancer, 2022, 21(1): 150.
doi: 10.1186/s12943-022-01605-w
pmid: 35864549
|
[6] |
ZHANG L, MA D L, LI F J, et al. Lnc-PKD2-2-3/miR-328/GPAM ceRNA network induces cholangiocarcinoma proliferation, invasion and 5-FU chemoresistance[J]. Front Oncol, 2022, 12: 871281.
doi: 10.3389/fonc.2022.871281
|
[7] |
QIU G C, MA D L, LI F J, et al. Lnc-PKD2-2-3, identified by long non-coding RNA expression profiling, is associated with pejorative tumor features and poor prognosis, enhances cancer stemness and may serve as cancer stem-cell marker in cholangiocarcinoma[J]. Int J Oncol, 2019, 55(1): 45-58.
doi: 10.3892/ijo.2019.4798
pmid: 31059014
|
[8] |
JIA L Q, GE X L, DU C, et al. EEF1A2 interacts with HSP90AB1 to promote lung adenocarcinoma metastasis via enhancing TGF-β/SMAD signalling[J]. Br J Cancer, 2021, 124(7): 1301-1311.
doi: 10.1038/s41416-020-01250-4
|
[9] |
HOU J, AERTS J, DEN HAMER B, et al. Gene expression-based classification of non-small cell lung carcinomas and survival prediction[J]. PLoS One, 2010, 5(4): e10312.
|
[10] |
ROUSSEAUX S, DEBERNARDI A, JACQUIAU B, et al. Ectopic activation of germline and placental genes identifies aggressive metastasis-prone lung cancers[J]. Sci Transl Med, 2013, 5(186): 186ra66.
|
[11] |
LI T F, ZHOU S, YANG Y, et al. LncRNA MNX1-AS1: a novel oncogenic propellant in cancers[J]. Biomedecine Pharmacother, 2022, 149: 112801.
|
[12] |
FARZANEH M, GHASEMIAN M, GHAEDRAHMATI F, et al. Functional roles of lncRNA-TUG1 in hepatocellular carcinoma[J]. Life Sci, 2022, 308: 120974.
doi: 10.1016/j.lfs.2022.120974
|
[13] |
FARZANEH M, NAJAFI S, ANBIYAEE O, et al. LncRNA MALAT1-related signaling pathways in osteosarcoma[J]. Clin Transl Oncol, 2023, 25(1): 21-32.
doi: 10.1007/s12094-022-02876-x
|
[14] |
ZHANG Y X, YUAN J, GAO Z M, et al. LncRNA TUC338 promotes invasion of lung cancer by activating MAPK pathway[J]. Eur Rev Med Pharmacol Sci, 2018, 22(2): 443-449.
|
[15] |
TIAN H, LIAN R, LI Y, et al. AKT-induced lncRNA VAL promotes EMT-independent metastasis through diminishing Trim16-dependent vimentin degradation[J]. Nat Commun, 2020, 11(1): 5127.
doi: 10.1038/s41467-020-18929-0
pmid: 33046716
|
[16] |
HASHEMI M, MOOSAVI M S, ABED H M, et al. Long non-coding RNA (lncRNA) H19 in human cancer: from proliferation and metastasis to therapy[J]. Pharmacol Res, 2022, 184: 106418.
doi: 10.1016/j.phrs.2022.106418
|